Moleculin Biotech Inc (MBRX)

Moleculin Biotech Inc (MBRX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $6.3M; returns 1 day +10.4%, 1 week +15.9%, 1 year -97.3%.

Moleculin Biotech Inc. (MBRX) is a late-stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. As a clinical-stage biopharmaceutical company, Moleculin Biotech's financial health is not driven by product sales, but by capital raises and pipeline progress. It relies almost entirely on equity financing.

Groups MBRX belongs to

• Biotechnology
• Recent Reverse Splits
• Pharmaceuticals
• Oncology
• Biopharmaceutical
• Clinical Stage
• Clinical Stage Biotech
• Cancer Therapeutics
• Clinical Stage Biopharma
• Healthcare
• R&D
• Life Sciences
• Hematologic Malignancies
• Hematology

MBRX financial model: income statement, cash flow and balance sheet